Chronic myelogenous leukemia (CML) is a malignant myeloid disorder characterized by the presence of a distinctive cytogenetic abnormality known as the Philadelphia chromosome.

Exposure to ionizing radiation is the only known risk factor with median presentation at age >50 years old.

Three phases of the disorder are chronic, accelerated and blast.

Choice of therapy is influenced by age, availability of a donor, comorbidities and phase of CML.

  1. American Cancer Society. What is chronic myeloid leukemia. American Cancer Society website. Feb 2016.
  2. Assouline S, Lipton JH. Monitoring response and resistance to treatment in chronic myeloid leukemia. Current Oncol. 2011 Apr;18(2):e71-e83. PMID: 21505592
  3. Baccarani M, Castagnetti F, Gugliotta G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Disease. 2014 Jan;6(1):e2014005. doi: 10.4084/MJHID.2014.005.
  4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet Recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug;122(6):872-884. doi: 10.1182/blood-2013-05-501569. PMID: 23803709
  5. Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2012 Oct;23(Suppl 7):vii72-vii77. doi:10.1093/annonc/mds228. PMID: 22997458
  6. Cancer Research UK. Types of treatment for chronic myeloid leukemia. Cancer Research UK website. Nov 2014.
  7. Cross NC, White HE, Colomer D. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. PMID: 25652737
  8. Deeg HJ, Sandmaier BM. Determining eligibility for hematopoietic cell transplantation. UptoDate website. Mar 2016.
  9. Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient’s perspective. Health Qual Life Outcomes. 2013 Oct;11:167. doi: 10.1186/1477-7525-11-167. PMID: 24099272
  10. National Cancer Institute. General information about chronic myelogenous leukemia (CML). National Cancer Institute website. Mar 2016.
  11. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1.2016. NCCN website. Sep 09, 2015.
  12. Negrin RS. Hematopoietic cell transplantation in chronic myeloid leukemia. UptoDate website. Apr 2016.
  13. Negrin RS, Schiffer CA. Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia. UptoDate website. Feb 2016.
  14. Negrin RS, Schiffer CA. Overview of the treatment of chronic myeloid leukemia. UptoDate website. treatment+of+chronic+myeloid+leukemia&selected Title=1%7E150. Feb 2016.
  15. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in accelerated phase. UptoDate website. of+chronic+myeloid+leukemia+in+accelerated +phase&selectedTitle=1%7E150. July 2015.
  16. Negrin RS, Schiffer CA. Treatment of myeloid leukemia in blast crisis. UptoDate website. http://www.uptodatecom/contents/treatment-of-chronic-myeloid-leukemia-in-blast-crisis? source=search_result&search=Treatment+of+chronic+ myeloid+leukemia+in+blast+crisis&selectedTitle=1~150. Sep 2014.
  17. Negrin RS, Schiffer CA. Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy. UptoDate website.§ionName=Omacetaxine&anchor=H24874435#H24874435. Apr 2016.
  18. Oehler VG. Update on current monitoring recommendations in chronic myeloid leukemia: practical points for clinical practice. Hematology Am Soc Hematol Educ Program. 2013;2013:176-183. doi: 10.1182/asheducation-2013.1.176. PMID: 24319179
  19. Rytting ME. Chronic myelogenous leukemia. MSD Manual. Oct 2014.
  20. Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treatment. 2015;2015:982395. doi: 10.1155/2015/982395. PMID: 26783469
  21. Van Etten RA. Cellular and molecular biology of chronic myeloid leukemia. UptoDate website. ?source=search_result&search=Cellular+and+molecular +biology+of+chronic+myeloid+leukemia& selectedTitle=1~150. Apr 2016.
  22. Van Etten RA. Clinical manifestations and diagnosis of chronic myeloid leukemia. UptoDate website. -and-diagnosis-of-chronic-myeloid-leukemia?source=search_result&search=clinical+manifestations+and+diagnosis+ of+chronic+myeloid+leukemia&selectedTitle=1~150. Apr 2016.
  23. Van Etten RA. Molecular genetics of chronic myeloid leukemia. UptoDate website. molecular-genetics-of-chronic-myeloid-leukemia? source=search_result&search=Quantitative+ RT-PCR+%28QPCR%29&selectedTitle=5~150. Sep 2015.
  24. Waclaw J, Sacha T, Soklosa T. Imatinib in the treatment of chronic myeloid leukemia: Current perspectives on optimal dose. Cancer Therapy Advisor. optimal-dosage/article/438571/. Sep 2015.
  25. World Health Organization. Chronic myelogenous leukemia. World Health Organization website. /applications/CML.pdf?ua=1. 2014.
  26. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology (NCCN Guidelines): chronic myeloid leukemia. Version 1.2017. NCCN website. 15 Nov 2016.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 13 Feb 2020

Immunotherapy-chemotherapy combinations, immunotherapy doublets, and combinations of immunotherapy with novel targeted agents are emerging as strategies for management of metastatic urothelial carcinoma (mUC) in view of the limitations with chemotherapy and single-agent immunotherapy, said an expert at the Uro-Oncology Asia 2020 conference. 

Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim, 27 Nov 2019
The current standard of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour with a rapid disease course, consists of maximum safe surgical resection followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the evidence and shared their clinical experience on the use of tumour treating fields (TTFields), a novel treatment modality for GBM.